

For Public Release
NZX Limited
Wellington

19 April 2021

Supply Activity added to Cannasouth Commercial Licence

Cannasouth Limited's (NZX:CBD, Cannasouth) wholly owned subsidiary Cannasouth Bioscience Limited has received approval for an additional activity under its commercial Medicinal Cannabis Licence by the Medicinal Cannabis Agency (Agency) for its facilities based in Hamilton. The new supply activity is additional to existing cultivation and possession for manufacture activities on the license.

This licence means Cannasouth is ready to distribute its imported own brand products, once registered with the Agency. Cannasouth submitted its product assessment applications for its first three products to the Agency in November 2020.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO, Cannasouth Limited
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO, Cannasouth Limited
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a biopharmaceutical research and product development company based in the Waikato heartland of New Zealand. The Company has been established to focus on the development of the medicinally beneficial attributes of cannabinoid compounds such as CBD, THC and associated chemical structures that are produced by the cannabis plant. Our goal is the development of next-generation cannabinoid medicines that support patients' health outcomes and improve their quality of life. Our products will be under GMP using environmentally friendly methods without the use of harmful chemicals or solvents, ensuring patients are treated with pure cannabinoid therapeutic compounds of the highest quality. The Cannasouth group holds commercial medicinal cannabis licenses granted by the Medicinal Cannabis Agency for cultivation, possession to manufacture, and supply activities.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>